--- a
+++ b/clusters/9knumclustersv2/clust_1411.txt
@@ -0,0 +1,31 @@
+A guidance regarding potential interactions with concomitant medications is provided
+Concomitant medications with another AR antagonist that would increase the risk of seizure (e.g., theophylline, aminophylline).
+EXCLUDED THERAPIES AND MEDICATIONS, PREVIOUS AND CONCOMITANT
+Concomitant Medications:
+There are currently no known concomitant medications that must be discontinued prior to administration of registration on study and for the duration of sEphB-HSA
+Concomitant medications:
+Concomitant medications, if taken within the last  days
+Concomitant medications:
+Any condition which could jeopardise the safety of the patient and his/her compliance in the study Excluded therapies and medications, previous and concomitant:
+Concomitant medications: patients receiving anticoagulation should be on stable dose  weeks prior to registration
+Requirement for concomitant medications that strongly induce or inhibit CYPA/
+Concomitant medications causing prolonged QT which cannot be discontinued or changed to a different medication prior to initiating study
+Patients requiring concomitant medications that are not able to be switched to a reasonable alternative
+Concomitant therapy medications that include corticosteroids (except as indicated in inclusion criteria)
+Participants may not be receiving any other investigational agents for  days prior to baseline evaluation and during the study intervention (which will be captured on the Concomitant Medications CRFs)
+Concomitant use of medications that may alter pharmacokinetics of enzalutamide
+EXCLUDED THERAPIES AND MEDICATIONS, PREVIOUS AND CONCOMITANT
+Excluded therapies and medications, previous and concomitant:
+Patients who are receiving concomitant D-antagonists (such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide) are NOT eligible for participation; patients must be off any such medications by the time of registration
+Concomitant Medication and Treatment: \r\n* All allowed medications or treatments should be kept to a minimum and recorded; all questions regarding concomitant medications should be referred to the Investigator
+Concomitant medications should be avoided (when possible) while on study
+Has a condition that requires the concomitant use of any of the protocol-excluded medications, supplements, or food products during the course of the study .
+Participants who take medications that are not recommended for concomitant use with their current antiretroviral regimen
+Concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against MM
+Concomitant medications that are known inducers of CYP.
+Concomitant use of medications that may alter pharmacokinetics of abiraterone or apalutamide
+No exclusion criteria relating to concomitant medications
+Concomitant use of medications known to induce a disulfiram-like reaction to alcohol
+There will be no exclusion criteria relating to concomitant medications
+Concomitant medications:
+Patients required to be on any of the concomitant medications are excluded